Table II.
Protective measures taken for COVID-19, source of information and influence of the pandemic
| Parameters (during COVID-19 pandemic) | SLE patients (n = 200) n (%) |
|---|---|
| Work affected | |
| Mild | 54 (27) |
| Moderate | 38 (19) |
| Severe | 26 (13) |
| Lost | 28 (14) |
| Protective measures taken | |
| Staying at home | 116 (58) |
| Wearing a mask | 148 (74) |
| Social distancing | 122 (62) |
| Using disinfectants/alcohol | 134 (67) |
| Source of information on COVID-19 | |
| Physicians | 56 (28) |
| Friends | 26 (13) |
| Media | 116 (58) |
| Social media | 150 (75) |
| Others (relatives/MOH/at work) | 88 (44) |
| Consider their knowledge sufficient | 120 (60) |
| Stopped or reduced taking NSAIDs | 40 (20) |
| Considered complementary therapy | 46 (23) |
| Received hydroxychloroquine for prevention | 10 (5) |
| Needed hospitalization | 34 (17) |
| Activity | 26 (13) |
| Pulmonary embolism | 6 (3) |
| Premature labor | 2 (1) |
| Found difficulty in hospitalization | 24 (12) |
| History of COVID-19 infection | |
| Close relatives affected | 76 (38) |
| Protective measures considered | 68 (34) |
| Patients with confirmed COVID-19 | 32 (16) |
| Free after treatment | 24 (12) |
| Carrier | 2 (1) |
| Still infected | 6 (3) |
| The disease was affected (flare) | 18 (9) |
| Cutaneous manifestations | 7 |
| Arthritis | 5 |
| Lupus nephritis | 2 |
| Livedoid vasculopathy | 1 |
| Lupus vasculitis | 1 |
| Unknown | 2 |
| Change in the lupus medications | 16 (8) |
MOH – Ministry of Health, NSAIDs – nonsteroidal anti-inflammatory drugs.